Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease

被引:1
作者
Kornbluh, Alexandra B. [1 ]
Campano, Victor M. [2 ]
Har, Claire [3 ]
Dwivedi, Pallavi [3 ]
Suslovic, William [3 ]
Sepeta, Leigh [4 ]
Kahn, Ilana [1 ]
机构
[1] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Hosp, Div Neonatol, Washington, DC 20052 USA
[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA
[3] Childrens Natl Hosp, Ctr Neurosci Res, Washington, DC USA
[4] Childrens Natl Hosp, Ctr Neurosci Res, Div Neuropsychol, Washington, DC USA
关键词
MOGAD; Pediatric neuroimmunology; Eosinophils; Cerebrospinal fluid; Biomarker;
D O I
10.1016/j.msard.2024.105526
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Eosinophils in cerebrospinal fluid (CSF) are an uncommon finding most often associated with parasitic infections, but have also been described in some neuroinflammatory disorders. Eosinophilic infiltration is not thought to be a typical feature of myelin oligodendrocyte glycoprotein antibody -associated disease (MOGAD). We aim to describe the rate of CSF eosinophil positivity in a cohort of pediatric MOGAD patients. Methods: Single -center retrospective chart review of pediatric MOGAD patients. Clinical and laboratory data was collected from the electronic medical record and analyzed. Results: Of 46 pediatric patients with positive serum myelin oligodendrocyte glycoprotein antibody (MOG-IgG) identified, 38 patients fulfilling internationally proposed MOGAD diagnostic criteria were included for analysis. 6 patients with MOGAD were excluded as no CSF data was available, and 2 patients with positive MOG-IgG but diagnosis more consistent with MS were excluded. Median age was 7.3 years, and 19/38 (50 %) were female. Acute disseminated encephalomyelitis (ADEM) was the most common presenting phenotype (23/38, 61 %), and other phenotypes included optic neuritis (10/38, 26 %), transverse myelitis (3/38, 8 %), and neuromyelitis optica spectrum disorder (NMOSD) (2/38, 5 %). 12 of 36 (33 %) patients with all lumbar puncture (LP) data available had CSF eosinophils present, with eosinophil mean of 3 % and range from 1 % to 18 % of CSF while blood cells. Conclusion: CSF eosinophils were present in one third of pediatric MOGAD patients, which is a higher rate than previously reported in either MOGAD or aquaporin-4 antibody positive NMOSD cohorts. Understanding the CSF composition of pediatric MOGAD patients helps to facilitate more prompt diagnosis and treatment and may shed light onto underlying pathologic mechanisms of disease with the goal to inform future therapeutic targets.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients
    Markovic, M
    Trajkovic, V
    Drulovic, J
    Mesaros, S
    Stojsavljevic, N
    Dujmovic, I
    Stojkovic, MM
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 211 (1-2) : 67 - 73
  • [42] Myelin oligodendrocyte glycoprotein antibody-associated disease with histopathologic features of primary CNS angiitis without demyelination: Case report and literature review
    Kim, Seongmi
    Lee, Suin
    Chung, Yeon Hak
    Ju, Hyunjin
    Suh, Yeon-Lim
    Min, Ju-Hong
    JOURNAL OF NEUROIMMUNOLOGY, 2024, 396
  • [43] Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Following Adenovirus Meningitis After First Delivery: Case Report and Literature Review
    Saito, Takashi
    Suzuki, Rieko
    Imai, Noboru
    Serizawa, Masahiro
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [44] Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated demyelination in children: A single-center cohort study in China
    Wang, Xin
    Zhao, Ruibin
    Yang, Huafang
    Liu, Chong
    Wang, Weiyi
    Liu, Tian
    Lu, Cui
    Chen, Didi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [45] Clinical features of the first attack with leukodystrophy-like phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disorders
    Jiang, Yan
    Tan, Chengbing
    Li, Xiujuan
    Jiang, Li
    Hong, Siqi
    Yuan, Ping
    Zheng, Heling
    Fan, Xiao
    Han, Wei
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2023, 83 (03) : 267 - 273
  • [46] Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) as a cause of new-onset refractory status epilepticus (NORSE): Case report and review of literature
    Vaingankar, Abhishek
    Agarwal, Ayush
    Garg, Divyani
    Gupta, Pranjal
    Garg, Ajay
    Radhakrishnan, Divya M.
    Pandit, Awadh K.
    Srivastava, Achal Kumar
    JOURNAL OF NEUROIMMUNOLOGY, 2025, 399
  • [47] EU paediatric MOG consortium consensus: Part 3-Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders
    Armangue, Thais
    Capobianco, Marco
    de Chalus, Alienor
    Laetitia, Giorgi
    Deiva, Kumaran
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2020, 29 : 22 - 31
  • [48] Systemic association of myelin oligodendrocyte glycoprotein antibody disease: A systematic review of literature
    Porey, Camelia
    Jaiswal, Binaya Kumar
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2024, 12 (02): : 71 - 79
  • [49] Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease
    Lotan, Itay
    Chen, John J.
    Hacohen, Yael
    Abdel-Mannan, Omar
    Mariotto, Sara
    Huda, Saif
    Gibbons, Emily
    Wilf-Yarkoni, Adi
    Hellmann, Mark A.
    Stiebel-Kalish, Hadas
    Pittock, Sean J.
    Flanagan, Eoin P.
    Molazadeh, Negar
    Anderson, Monique
    Salky, Rebecca
    Romanow, Gabriela
    Schindler, Patrick
    Duchow, Ankelien Solveig
    Paul, Friedemann
    Levy, Michael
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (09) : 1080 - 1089
  • [50] MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease
    Contentti, Edgar Carnero
    Okuda, Darin T.
    Rojas, Juan I.
    Chien, Claudia
    Paul, Friedemman
    Alonso, Ricardo
    JOURNAL OF NEUROIMAGING, 2023, 33 (05) : 688 - 702